Xtandi Scores Regulatory Win in China for Non-Metastatic Castration-Resistant Prostate Cancer
Prostate cancer is the most commonly seen male urology-related cancers in China and the second most common cancer in men worldwide. Amongst all other types of prostate cancers, castration-resistant prostate …
Read More